To investigate the significance of the C - terminal Abl actin - binding domain within Bcr / Abl p190 in the development of leukemia / lymphoma in vivo, mutant p190 DNA constructs were used to generate transgenic mice.	"Abl	52	55	Gene_or_gene_product"	"actin	56	61	Gene_or_gene_product"	"Bcr / Abl p190	86	100	Gene_or_gene_product"	"leukemia	123	131	Cancer"	"lymphoma	134	142	Cancer"	"p190	159	163	Gene_or_gene_product"	"DNA	164	167	Cellular_component"	"transgenic mice	201	216	Organism"	"[{""token"": ""Abl"", ""start_span"": 52, ""end_span"": 55, ""type"": ""Gene_or_gene_product""}, {""token"": ""actin"", ""start_span"": 56, ""end_span"": 61, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcr / Abl p190"", ""start_span"": 86, ""end_span"": 100, ""type"": ""Gene_or_gene_product""}, {""token"": ""leukemia"", ""start_span"": 123, ""end_span"": 131, ""type"": ""Cancer""}, {""token"": ""lymphoma"", ""start_span"": 134, ""end_span"": 142, ""type"": ""Cancer""}, {""token"": ""p190"", ""start_span"": 159, ""end_span"": 163, ""type"": ""Gene_or_gene_product""}, {""token"": ""DNA"", ""start_span"": 164, ""end_span"": 167, ""type"": ""Cellular_component""}, {""token"": ""transgenic mice"", ""start_span"": 201, ""end_span"": 216, ""type"": ""Organism""}]"
Western blot analysis of involved hematologic tissues of the p190 del C transgenics with end - stage disease showed high - level expression of the transgene and tyrosine phosphorylation of Cbl and Hef1 / Cas, proteins previously shown to be affected by Bcr / Abl.	"hematologic tissues	34	53	Tissue"	"p190	61	65	Gene_or_gene_product"	"transgenics	72	83	Organism"	"tyrosine	161	169	Amino_acid"	"Cbl	189	192	Gene_or_gene_product"	"Hef1	197	201	Gene_or_gene_product"	"Cas	204	207	Gene_or_gene_product"	"Bcr / Abl	253	262	Gene_or_gene_product"	"[{""token"": ""hematologic tissues"", ""start_span"": 34, ""end_span"": 53, ""type"": ""Tissue""}, {""token"": ""p190"", ""start_span"": 61, ""end_span"": 65, ""type"": ""Gene_or_gene_product""}, {""token"": ""transgenics"", ""start_span"": 72, ""end_span"": 83, ""type"": ""Organism""}, {""token"": ""tyrosine"", ""start_span"": 161, ""end_span"": 169, ""type"": ""Amino_acid""}, {""token"": ""Cbl"", ""start_span"": 189, ""end_span"": 192, ""type"": ""Gene_or_gene_product""}, {""token"": ""Hef1"", ""start_span"": 197, ""end_span"": 201, ""type"": ""Gene_or_gene_product""}, {""token"": ""Cas"", ""start_span"": 204, ""end_span"": 207, ""type"": ""Gene_or_gene_product""}, {""token"": ""Bcr / Abl"", ""start_span"": 253, ""end_span"": 262, ""type"": ""Gene_or_gene_product""}]"
The results showed that expression levels of both nm23 - H1 and nm23 - H2 mRNA varied in normal buccal mucosa, leukoplakia, adjacent nontumorous mucosa, submandibular gland, CBM and lymph nodes with or without metastasis.	"nm23 - H1	50	59	Gene_or_gene_product"	"nm23 - H2	64	73	Gene_or_gene_product"	"buccal mucosa	96	109	Multi"	"leukoplakia	111	122	Pathological_formation"	"nontumorous mucosa	133	151	Multi"	"submandibular gland	153	172	Organ"	"CBM	174	177	Cancer"	"lymph nodes	182	193	Multi"	"[{""token"": ""nm23 - H1"", ""start_span"": 50, ""end_span"": 59, ""type"": ""Gene_or_gene_product""}, {""token"": ""nm23 - H2"", ""start_span"": 64, ""end_span"": 73, ""type"": ""Gene_or_gene_product""}, {""token"": ""buccal mucosa"", ""start_span"": 96, ""end_span"": 109, ""type"": ""Multi""}, {""token"": ""leukoplakia"", ""start_span"": 111, ""end_span"": 122, ""type"": ""Pathological_formation""}, {""token"": ""nontumorous mucosa"", ""start_span"": 133, ""end_span"": 151, ""type"": ""Multi""}, {""token"": ""submandibular gland"", ""start_span"": 153, ""end_span"": 172, ""type"": ""Organ""}, {""token"": ""CBM"", ""start_span"": 174, ""end_span"": 177, ""type"": ""Cancer""}, {""token"": ""lymph nodes"", ""start_span"": 182, ""end_span"": 193, ""type"": ""Multi""}]"
The similarity between RhoA effects and thyroid transformation by Ras suggests that RhoA may act as a downstream effector of Ras; in fact, the dominant negative RhoA N19 abolished the down - regulatory effect of Ras V12 over the Tg promoter.	"RhoA	23	27	Gene_or_gene_product"	"thyroid	40	47	Cell"	"Ras	66	69	Gene_or_gene_product"	"RhoA	84	88	Gene_or_gene_product"	"Ras	125	128	Gene_or_gene_product"	"RhoA	161	165	Gene_or_gene_product"	"Ras	212	215	Gene_or_gene_product"	"Tg	229	231	Gene_or_gene_product"	"[{""token"": ""RhoA"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Gene_or_gene_product""}, {""token"": ""thyroid"", ""start_span"": 40, ""end_span"": 47, ""type"": ""Cell""}, {""token"": ""Ras"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Gene_or_gene_product""}, {""token"": ""RhoA"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ras"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Gene_or_gene_product""}, {""token"": ""RhoA"", ""start_span"": 161, ""end_span"": 165, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ras"", ""start_span"": 212, ""end_span"": 215, ""type"": ""Gene_or_gene_product""}, {""token"": ""Tg"", ""start_span"": 229, ""end_span"": 231, ""type"": ""Gene_or_gene_product""}]"
METHODS: The authors evaluated plasma endostatin ( PE) levels using an enzyme linked immunoassay in 71 patients with acute myeloid leukemia ( AML) and 43 patients with myelodysplastic syndrome ( MDS), and correlated PE with various clinical parameters.	"plasma	31	37	Organism_substance"	"endostatin	38	48	Gene_or_gene_product"	"PE	51	53	Gene_or_gene_product"	"patients	103	111	Organism"	"acute myeloid leukemia	117	139	Cancer"	"AML	142	145	Cancer"	"patients	154	162	Organism"	"PE	216	218	Gene_or_gene_product"	"[{""token"": ""plasma"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Organism_substance""}, {""token"": ""endostatin"", ""start_span"": 38, ""end_span"": 48, ""type"": ""Gene_or_gene_product""}, {""token"": ""PE"", ""start_span"": 51, ""end_span"": 53, ""type"": ""Gene_or_gene_product""}, {""token"": ""patients"", ""start_span"": 103, ""end_span"": 111, ""type"": ""Organism""}, {""token"": ""acute myeloid leukemia"", ""start_span"": 117, ""end_span"": 139, ""type"": ""Cancer""}, {""token"": ""AML"", ""start_span"": 142, ""end_span"": 145, ""type"": ""Cancer""}, {""token"": ""patients"", ""start_span"": 154, ""end_span"": 162, ""type"": ""Organism""}, {""token"": ""PE"", ""start_span"": 216, ""end_span"": 218, ""type"": ""Gene_or_gene_product""}]"
TS - 1 is a new, oral anticancer agent composed of two modulators, gimeracil ( CDHP) and oteracil potassium ( Oxo) are mixed with tegafur in a ratio of 1: 0. 4: 1.	"TS - 1	0	6	Chemical"	"oral	17	21	Organism_subdivision"	"anticancer	22	32	Cancer"	"gimeracil	67	76	Chemical"	"CDHP	79	83	Chemical"	"oteracil potassium	89	107	Chemical"	"Oxo	110	113	Chemical"	"tegafur	130	137	Chemical"	"[{""token"": ""TS - 1"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Chemical""}, {""token"": ""oral"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Organism_subdivision""}, {""token"": ""anticancer"", ""start_span"": 22, ""end_span"": 32, ""type"": ""Cancer""}, {""token"": ""gimeracil"", ""start_span"": 67, ""end_span"": 76, ""type"": ""Chemical""}, {""token"": ""CDHP"", ""start_span"": 79, ""end_span"": 83, ""type"": ""Chemical""}, {""token"": ""oteracil potassium"", ""start_span"": 89, ""end_span"": 107, ""type"": ""Chemical""}, {""token"": ""Oxo"", ""start_span"": 110, ""end_span"": 113, ""type"": ""Chemical""}, {""token"": ""tegafur"", ""start_span"": 130, ""end_span"": 137, ""type"": ""Chemical""}]"
Exposure of SKOV - 3 cells to paclitaxel or carboplatin along with 317615 2HCl resulted in cell survivals that reflected additivity of 317615 x 2HCl with paclitaxel and greater - than - additive cytotoxicity with carboplatin.	"SKOV - 3 cells	12	26	Cell"	"paclitaxel	30	40	Chemical"	"carboplatin	44	55	Chemical"	"317615 2HCl	67	78	Chemical"	"cell	91	95	Cell"	"317615 x 2HCl	135	148	Chemical"	"paclitaxel	154	164	Chemical"	"carboplatin	213	224	Chemical"	"[{""token"": ""SKOV - 3 cells"", ""start_span"": 12, ""end_span"": 26, ""type"": ""Cell""}, {""token"": ""paclitaxel"", ""start_span"": 30, ""end_span"": 40, ""type"": ""Chemical""}, {""token"": ""carboplatin"", ""start_span"": 44, ""end_span"": 55, ""type"": ""Chemical""}, {""token"": ""317615 2HCl"", ""start_span"": 67, ""end_span"": 78, ""type"": ""Chemical""}, {""token"": ""cell"", ""start_span"": 91, ""end_span"": 95, ""type"": ""Cell""}, {""token"": ""317615 x 2HCl"", ""start_span"": 135, ""end_span"": 148, ""type"": ""Chemical""}, {""token"": ""paclitaxel"", ""start_span"": 154, ""end_span"": 164, ""type"": ""Chemical""}, {""token"": ""carboplatin"", ""start_span"": 213, ""end_span"": 224, ""type"": ""Chemical""}]"
However, re - expression of wt - p53 in EU - 4 cells could restore the doxorubicin - p53 - survivin pathway, resulting in significantly decreased survivin expression and increased apoptosis in these cells after doxorubicin treatment.	"p53	33	36	Gene_or_gene_product"	"EU - 4 cells	40	52	Cell"	"doxorubicin	71	82	Chemical"	"p53	85	88	Gene_or_gene_product"	"survivin	91	99	Gene_or_gene_product"	"survivin	146	154	Gene_or_gene_product"	"cells	199	204	Cell"	"doxorubicin	211	222	Chemical"	"[{""token"": ""p53"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Gene_or_gene_product""}, {""token"": ""EU - 4 cells"", ""start_span"": 40, ""end_span"": 52, ""type"": ""Cell""}, {""token"": ""doxorubicin"", ""start_span"": 71, ""end_span"": 82, ""type"": ""Chemical""}, {""token"": ""p53"", ""start_span"": 85, ""end_span"": 88, ""type"": ""Gene_or_gene_product""}, {""token"": ""survivin"", ""start_span"": 91, ""end_span"": 99, ""type"": ""Gene_or_gene_product""}, {""token"": ""survivin"", ""start_span"": 146, ""end_span"": 154, ""type"": ""Gene_or_gene_product""}, {""token"": ""cells"", ""start_span"": 199, ""end_span"": 204, ""type"": ""Cell""}, {""token"": ""doxorubicin"", ""start_span"": 211, ""end_span"": 222, ""type"": ""Chemical""}]"
These data provide the first demonstration of IGF - I / II expression in the human lung in early gestation and indicate that the IGF family of growth factors, acting through the IGF - IR, is required as a survival factor during normal human lung vascularization.	"IGF - I	46	53	Gene_or_gene_product"	"II	56	58	Gene_or_gene_product"	"human	77	82	Organism"	"lung	83	87	Organ"	"IGF	129	132	Gene_or_gene_product"	"IGF - IR	178	186	Gene_or_gene_product"	"human	235	240	Organism"	"lung	241	245	Organ"	"[{""token"": ""IGF - I"", ""start_span"": 46, ""end_span"": 53, ""type"": ""Gene_or_gene_product""}, {""token"": ""II"", ""start_span"": 56, ""end_span"": 58, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Organism""}, {""token"": ""lung"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Organ""}, {""token"": ""IGF"", ""start_span"": 129, ""end_span"": 132, ""type"": ""Gene_or_gene_product""}, {""token"": ""IGF - IR"", ""start_span"": 178, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 235, ""end_span"": 240, ""type"": ""Organism""}, {""token"": ""lung"", ""start_span"": 241, ""end_span"": 245, ""type"": ""Organ""}]"
The tumour suppressor p53 and interferon - alpha and - beta ( IFN - alpha / beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship.	"tumour	4	10	Cancer"	"p53	22	25	Gene_or_gene_product"	"interferon - alpha	30	48	Gene_or_gene_product"	"- beta	53	59	Gene_or_gene_product"	"IFN - alpha	62	73	Gene_or_gene_product"	"beta	76	80	Gene_or_gene_product"	"cancerous cells	130	145	Cell"	"antiviral	153	162	Organism"	"[{""token"": ""tumour"", ""start_span"": 4, ""end_span"": 10, ""type"": ""Cancer""}, {""token"": ""p53"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Gene_or_gene_product""}, {""token"": ""interferon - alpha"", ""start_span"": 30, ""end_span"": 48, ""type"": ""Gene_or_gene_product""}, {""token"": ""- beta"", ""start_span"": 53, ""end_span"": 59, ""type"": ""Gene_or_gene_product""}, {""token"": ""IFN - alpha"", ""start_span"": 62, ""end_span"": 73, ""type"": ""Gene_or_gene_product""}, {""token"": ""beta"", ""start_span"": 76, ""end_span"": 80, ""type"": ""Gene_or_gene_product""}, {""token"": ""cancerous cells"", ""start_span"": 130, ""end_span"": 145, ""type"": ""Cell""}, {""token"": ""antiviral"", ""start_span"": 153, ""end_span"": 162, ""type"": ""Organism""}]"
Herein, we report that these compounds effectively inhibited SDF - 1 - induced migration of human breast cancer cells ( MDA - MB - 231), human leukemia T cells ( Sup - T1) and human umbilical vein endothelial cells at concentrations of 10 - 100 nM in vitro.	"SDF - 1	61	68	Gene_or_gene_product"	"human	92	97	Organism"	"breast cancer cells	98	117	Cell"	"MDA - MB - 231	120	134	Cell"	"human	137	142	Organism"	"leukemia T cells	143	159	Cell"	"Sup - T1	162	170	Cell"	"human umbilical vein endothelial cells	176	214	Cell"	"[{""token"": ""SDF - 1"", ""start_span"": 61, ""end_span"": 68, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 92, ""end_span"": 97, ""type"": ""Organism""}, {""token"": ""breast cancer cells"", ""start_span"": 98, ""end_span"": 117, ""type"": ""Cell""}, {""token"": ""MDA - MB - 231"", ""start_span"": 120, ""end_span"": 134, ""type"": ""Cell""}, {""token"": ""human"", ""start_span"": 137, ""end_span"": 142, ""type"": ""Organism""}, {""token"": ""leukemia T cells"", ""start_span"": 143, ""end_span"": 159, ""type"": ""Cell""}, {""token"": ""Sup - T1"", ""start_span"": 162, ""end_span"": 170, ""type"": ""Cell""}, {""token"": ""human umbilical vein endothelial cells"", ""start_span"": 176, ""end_span"": 214, ""type"": ""Cell""}]"
In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG II levels, elevated ANG II levels by transgenic overexpression of angiotensinogen ( AOGEN), or in AT2 receptor - deficient mice.	"alginate	37	45	Chemical"	"mice	76	80	Organism"	"ANG II	93	99	Gene_or_gene_product"	"ANG II	117	123	Gene_or_gene_product"	"angiotensinogen	163	178	Gene_or_gene_product"	"AOGEN	181	186	Gene_or_gene_product"	"AT2 receptor	195	207	Gene_or_gene_product"	"mice	220	224	Organism"	"[{""token"": ""alginate"", ""start_span"": 37, ""end_span"": 45, ""type"": ""Chemical""}, {""token"": ""mice"", ""start_span"": 76, ""end_span"": 80, ""type"": ""Organism""}, {""token"": ""ANG II"", ""start_span"": 93, ""end_span"": 99, ""type"": ""Gene_or_gene_product""}, {""token"": ""ANG II"", ""start_span"": 117, ""end_span"": 123, ""type"": ""Gene_or_gene_product""}, {""token"": ""angiotensinogen"", ""start_span"": 163, ""end_span"": 178, ""type"": ""Gene_or_gene_product""}, {""token"": ""AOGEN"", ""start_span"": 181, ""end_span"": 186, ""type"": ""Gene_or_gene_product""}, {""token"": ""AT2 receptor"", ""start_span"": 195, ""end_span"": 207, ""type"": ""Gene_or_gene_product""}, {""token"": ""mice"", ""start_span"": 220, ""end_span"": 224, ""type"": ""Organism""}]"
We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin - converting enzyme ( ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor.	"ANG II	60	66	Gene_or_gene_product"	"angiotensin - converting enzyme	74	105	Gene_or_gene_product"	"ACE	108	111	Gene_or_gene_product"	"enalapril	123	132	Chemical"	"AT1 receptor	140	152	Gene_or_gene_product"	"losartan	164	172	Chemical"	"ANG II	254	260	Gene_or_gene_product"	"AT1 receptor	273	285	Gene_or_gene_product"	"[{""token"": ""ANG II"", ""start_span"": 60, ""end_span"": 66, ""type"": ""Gene_or_gene_product""}, {""token"": ""angiotensin - converting enzyme"", ""start_span"": 74, ""end_span"": 105, ""type"": ""Gene_or_gene_product""}, {""token"": ""ACE"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Gene_or_gene_product""}, {""token"": ""enalapril"", ""start_span"": 123, ""end_span"": 132, ""type"": ""Chemical""}, {""token"": ""AT1 receptor"", ""start_span"": 140, ""end_span"": 152, ""type"": ""Gene_or_gene_product""}, {""token"": ""losartan"", ""start_span"": 164, ""end_span"": 172, ""type"": ""Chemical""}, {""token"": ""ANG II"", ""start_span"": 254, ""end_span"": 260, ""type"": ""Gene_or_gene_product""}, {""token"": ""AT1 receptor"", ""start_span"": 273, ""end_span"": 285, ""type"": ""Gene_or_gene_product""}]"
Considering also that clusterin is downregulated during prostate cancer onset and progression, and that its upregulation has inhibited DNA synthesis and cell cycle progression of immortalized human prostate epithelial cells, we suggest that clusterin might be a new anti - oncogene in the prostate.	"clusterin	22	31	Gene_or_gene_product"	"prostate cancer	56	71	Cancer"	"DNA	135	138	Cellular_component"	"cell	153	157	Cell"	"human	192	197	Organism"	"prostate epithelial cells	198	223	Cell"	"clusterin	241	250	Gene_or_gene_product"	"prostate	289	297	Organ"	"[{""token"": ""clusterin"", ""start_span"": 22, ""end_span"": 31, ""type"": ""Gene_or_gene_product""}, {""token"": ""prostate cancer"", ""start_span"": 56, ""end_span"": 71, ""type"": ""Cancer""}, {""token"": ""DNA"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Cellular_component""}, {""token"": ""cell"", ""start_span"": 153, ""end_span"": 157, ""type"": ""Cell""}, {""token"": ""human"", ""start_span"": 192, ""end_span"": 197, ""type"": ""Organism""}, {""token"": ""prostate epithelial cells"", ""start_span"": 198, ""end_span"": 223, ""type"": ""Cell""}, {""token"": ""clusterin"", ""start_span"": 241, ""end_span"": 250, ""type"": ""Gene_or_gene_product""}, {""token"": ""prostate"", ""start_span"": 289, ""end_span"": 297, ""type"": ""Organ""}]"
Here we demonstrate that bone marrow - derived haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 ( VEGFR1; also known as Flt1) home to tumour - specific pre - metastatic sites and form cellular clusters before the arrival of tumour cells.	"bone marrow - derived haematopoietic progenitor cells	25	78	Cell"	"vascular endothelial growth factor receptor 1	92	137	Gene_or_gene_product"	"VEGFR1	140	146	Gene_or_gene_product"	"Flt1	162	166	Gene_or_gene_product"	"tumour	176	182	Cancer"	"sites	211	216	Multi"	"cellular clusters	226	243	Cell"	"tumour cells	266	278	Cell"	"[{""token"": ""bone marrow - derived haematopoietic progenitor cells"", ""start_span"": 25, ""end_span"": 78, ""type"": ""Cell""}, {""token"": ""vascular endothelial growth factor receptor 1"", ""start_span"": 92, ""end_span"": 137, ""type"": ""Gene_or_gene_product""}, {""token"": ""VEGFR1"", ""start_span"": 140, ""end_span"": 146, ""type"": ""Gene_or_gene_product""}, {""token"": ""Flt1"", ""start_span"": 162, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumour"", ""start_span"": 176, ""end_span"": 182, ""type"": ""Cancer""}, {""token"": ""sites"", ""start_span"": 211, ""end_span"": 216, ""type"": ""Multi""}, {""token"": ""cellular clusters"", ""start_span"": 226, ""end_span"": 243, ""type"": ""Cell""}, {""token"": ""tumour cells"", ""start_span"": 266, ""end_span"": 278, ""type"": ""Cell""}]"
We also show that VEGFR1 + cells express VLA - 4 ( also known as integrin alpha4beta1), and that tumour - specific growth factors upregulate fibronectin - - a VLA - 4 ligand - - in resident fibroblasts, providing a permissive niche for incoming tumour cells.	"VEGFR1	18	24	Gene_or_gene_product"	"VLA - 4	41	48	Gene_or_gene_product"	"integrin alpha4beta1	65	85	Gene_or_gene_product"	"tumour	97	103	Cancer"	"fibronectin	141	152	Gene_or_gene_product"	"VLA - 4	159	166	Gene_or_gene_product"	"fibroblasts	190	201	Cell"	"tumour cells	245	257	Cell"	"[{""token"": ""VEGFR1"", ""start_span"": 18, ""end_span"": 24, ""type"": ""Gene_or_gene_product""}, {""token"": ""VLA - 4"", ""start_span"": 41, ""end_span"": 48, ""type"": ""Gene_or_gene_product""}, {""token"": ""integrin alpha4beta1"", ""start_span"": 65, ""end_span"": 85, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumour"", ""start_span"": 97, ""end_span"": 103, ""type"": ""Cancer""}, {""token"": ""fibronectin"", ""start_span"": 141, ""end_span"": 152, ""type"": ""Gene_or_gene_product""}, {""token"": ""VLA - 4"", ""start_span"": 159, ""end_span"": 166, ""type"": ""Gene_or_gene_product""}, {""token"": ""fibroblasts"", ""start_span"": 190, ""end_span"": 201, ""type"": ""Cell""}, {""token"": ""tumour cells"", ""start_span"": 245, ""end_span"": 257, ""type"": ""Cell""}]"
Because PIM - 1 is a STAT5 target gene, we analyzed the role of the family of PIM serine / threonine kinases ( PIM - 1 to PIM - 3) in PTK - mediated transformation of hematopoietic cells.	"PIM - 1	8	15	Gene_or_gene_product"	"STAT5	21	26	Gene_or_gene_product"	"serine	82	88	Amino_acid"	"threonine	91	100	Amino_acid"	"PIM - 1	111	118	Gene_or_gene_product"	"PIM - 3	122	129	Gene_or_gene_product"	"PTK	134	137	Gene_or_gene_product"	"hematopoietic cells	167	186	Cell"	"[{""token"": ""PIM - 1"", ""start_span"": 8, ""end_span"": 15, ""type"": ""Gene_or_gene_product""}, {""token"": ""STAT5"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Gene_or_gene_product""}, {""token"": ""serine"", ""start_span"": 82, ""end_span"": 88, ""type"": ""Amino_acid""}, {""token"": ""threonine"", ""start_span"": 91, ""end_span"": 100, ""type"": ""Amino_acid""}, {""token"": ""PIM - 1"", ""start_span"": 111, ""end_span"": 118, ""type"": ""Gene_or_gene_product""}, {""token"": ""PIM - 3"", ""start_span"": 122, ""end_span"": 129, ""type"": ""Gene_or_gene_product""}, {""token"": ""PTK"", ""start_span"": 134, ""end_span"": 137, ""type"": ""Gene_or_gene_product""}, {""token"": ""hematopoietic cells"", ""start_span"": 167, ""end_span"": 186, ""type"": ""Cell""}]"
Interestingly, cells transformed by FLT3 and BCR / ABL mutations that confer resistance to small - molecule tyrosine kinase inhibitors were still sensitive to knockdown of PIM - 2, or PIM - 1 and PIM - 2 by RNAi.	"cells	15	20	Cell"	"FLT3	36	40	Gene_or_gene_product"	"BCR	45	48	Gene_or_gene_product"	"ABL	51	54	Gene_or_gene_product"	"small - molecule tyrosine kinase	91	123	Gene_or_gene_product"	"PIM - 2	172	179	Gene_or_gene_product"	"PIM - 1	184	191	Gene_or_gene_product"	"PIM - 2	196	203	Gene_or_gene_product"	"[{""token"": ""cells"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Cell""}, {""token"": ""FLT3"", ""start_span"": 36, ""end_span"": 40, ""type"": ""Gene_or_gene_product""}, {""token"": ""BCR"", ""start_span"": 45, ""end_span"": 48, ""type"": ""Gene_or_gene_product""}, {""token"": ""ABL"", ""start_span"": 51, ""end_span"": 54, ""type"": ""Gene_or_gene_product""}, {""token"": ""small - molecule tyrosine kinase"", ""start_span"": 91, ""end_span"": 123, ""type"": ""Gene_or_gene_product""}, {""token"": ""PIM - 2"", ""start_span"": 172, ""end_span"": 179, ""type"": ""Gene_or_gene_product""}, {""token"": ""PIM - 1"", ""start_span"": 184, ""end_span"": 191, ""type"": ""Gene_or_gene_product""}, {""token"": ""PIM - 2"", ""start_span"": 196, ""end_span"": 203, ""type"": ""Gene_or_gene_product""}]"
The caprine placenta is usually considered to have increased interhemal distance compared with endotheliochorial and hemochorial types: our results suggest that the very extensive development of sinusoids and crypts may compensate for any negative consequences of the placental architecture.	"caprine	4	11	Organism"	"placenta	12	20	Organ"	"interhemal	61	71	Immaterial_anatomical_entity"	"endotheliochorial	95	112	Organ"	"hemochorial types	117	134	Organ"	"sinusoids	195	204	Tissue"	"crypts	209	215	Multi"	"placental	268	277	Organ"	"[{""token"": ""caprine"", ""start_span"": 4, ""end_span"": 11, ""type"": ""Organism""}, {""token"": ""placenta"", ""start_span"": 12, ""end_span"": 20, ""type"": ""Organ""}, {""token"": ""interhemal"", ""start_span"": 61, ""end_span"": 71, ""type"": ""Immaterial_anatomical_entity""}, {""token"": ""endotheliochorial"", ""start_span"": 95, ""end_span"": 112, ""type"": ""Organ""}, {""token"": ""hemochorial types"", ""start_span"": 117, ""end_span"": 134, ""type"": ""Organ""}, {""token"": ""sinusoids"", ""start_span"": 195, ""end_span"": 204, ""type"": ""Tissue""}, {""token"": ""crypts"", ""start_span"": 209, ""end_span"": 215, ""type"": ""Multi""}, {""token"": ""placental"", ""start_span"": 268, ""end_span"": 277, ""type"": ""Organ""}]"
This analysis revealed a higher expression of vessel maturation and stabilisation factors ( placental growth factor, PDGFB1, angiopoietin 1) in CC - RCC with high MVD, a group of CC - RCC highly enriched in low nuclear grade CC - RCC, with low ECP%.	"vessel	46	52	Multi"	"placental growth factor	92	115	Gene_or_gene_product"	"PDGFB1	117	123	Gene_or_gene_product"	"angiopoietin 1	125	139	Gene_or_gene_product"	"CC - RCC	144	152	Cancer"	"CC - RCC	179	187	Cancer"	"nuclear	211	218	Cellular_component"	"CC - RCC	225	233	Cancer"	"[{""token"": ""vessel"", ""start_span"": 46, ""end_span"": 52, ""type"": ""Multi""}, {""token"": ""placental growth factor"", ""start_span"": 92, ""end_span"": 115, ""type"": ""Gene_or_gene_product""}, {""token"": ""PDGFB1"", ""start_span"": 117, ""end_span"": 123, ""type"": ""Gene_or_gene_product""}, {""token"": ""angiopoietin 1"", ""start_span"": 125, ""end_span"": 139, ""type"": ""Gene_or_gene_product""}, {""token"": ""CC - RCC"", ""start_span"": 144, ""end_span"": 152, ""type"": ""Cancer""}, {""token"": ""CC - RCC"", ""start_span"": 179, ""end_span"": 187, ""type"": ""Cancer""}, {""token"": ""nuclear"", ""start_span"": 211, ""end_span"": 218, ""type"": ""Cellular_component""}, {""token"": ""CC - RCC"", ""start_span"": 225, ""end_span"": 233, ""type"": ""Cancer""}]"
In 1983, Harold Dvorak and his colleagues were the first to show that tumor cells secreted vascular permeability factor ( VPF) and that a blocking antibody to VPF could prevent the edema and fluid accumulation that is characteristic of human cancers.	"tumor cells	70	81	Cell"	"vascular permeability factor	91	119	Gene_or_gene_product"	"VPF	122	125	Gene_or_gene_product"	"VPF	159	162	Gene_or_gene_product"	"edema	181	186	Pathological_formation"	"fluid	191	196	Organism_substance"	"human	236	241	Organism"	"cancers	242	249	Cancer"	"[{""token"": ""tumor cells"", ""start_span"": 70, ""end_span"": 81, ""type"": ""Cell""}, {""token"": ""vascular permeability factor"", ""start_span"": 91, ""end_span"": 119, ""type"": ""Gene_or_gene_product""}, {""token"": ""VPF"", ""start_span"": 122, ""end_span"": 125, ""type"": ""Gene_or_gene_product""}, {""token"": ""VPF"", ""start_span"": 159, ""end_span"": 162, ""type"": ""Gene_or_gene_product""}, {""token"": ""edema"", ""start_span"": 181, ""end_span"": 186, ""type"": ""Pathological_formation""}, {""token"": ""fluid"", ""start_span"": 191, ""end_span"": 196, ""type"": ""Organism_substance""}, {""token"": ""human"", ""start_span"": 236, ""end_span"": 241, ""type"": ""Organism""}, {""token"": ""cancers"", ""start_span"": 242, ""end_span"": 249, ""type"": ""Cancer""}]"
In the current study, Hedgehog signaling in tumor related vasculature and microenvironment was examined using human umbilical vein endothelial cells and B16F0 ( murine melanoma) tumors models.	"Hedgehog	22	30	Gene_or_gene_product"	"tumor	44	49	Cancer"	"vasculature	58	69	Multi"	"human umbilical vein endothelial cells	110	148	Cell"	"B16F0	153	158	Cell"	"murine	161	167	Organism"	"melanoma	168	176	Cancer"	"tumors	178	184	Cancer"	"[{""token"": ""Hedgehog"", ""start_span"": 22, ""end_span"": 30, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Cancer""}, {""token"": ""vasculature"", ""start_span"": 58, ""end_span"": 69, ""type"": ""Multi""}, {""token"": ""human umbilical vein endothelial cells"", ""start_span"": 110, ""end_span"": 148, ""type"": ""Cell""}, {""token"": ""B16F0"", ""start_span"": 153, ""end_span"": 158, ""type"": ""Cell""}, {""token"": ""murine"", ""start_span"": 161, ""end_span"": 167, ""type"": ""Organism""}, {""token"": ""melanoma"", ""start_span"": 168, ""end_span"": 176, ""type"": ""Cancer""}, {""token"": ""tumors"", ""start_span"": 178, ""end_span"": 184, ""type"": ""Cancer""}]"
Interestingly, CDK4 - expressing cells, but not CDK2 - expressing cells, strongly synergize with lack of p27 ( Kip1) to generate pituitary carcinomas that appear with shortened latency and are drastically more aggressive than those arising in p27 ( - / -) mice.	"CDK4	15	19	Gene_or_gene_product"	"cells	33	38	Cell"	"CDK2	48	52	Gene_or_gene_product"	"cells	66	71	Cell"	"p27	105	108	Gene_or_gene_product"	"Kip1	111	115	Gene_or_gene_product"	"pituitary carcinomas	129	149	Cancer"	"p27	243	246	Gene_or_gene_product"	"[{""token"": ""CDK4"", ""start_span"": 15, ""end_span"": 19, ""type"": ""Gene_or_gene_product""}, {""token"": ""cells"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Cell""}, {""token"": ""CDK2"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Gene_or_gene_product""}, {""token"": ""cells"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Cell""}, {""token"": ""p27"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Gene_or_gene_product""}, {""token"": ""Kip1"", ""start_span"": 111, ""end_span"": 115, ""type"": ""Gene_or_gene_product""}, {""token"": ""pituitary carcinomas"", ""start_span"": 129, ""end_span"": 149, ""type"": ""Cancer""}, {""token"": ""p27"", ""start_span"": 243, ""end_span"": 246, ""type"": ""Gene_or_gene_product""}]"
Immunohistochemistry examinations in the human surgical specimens have shown that a downregulation of TSP - 1 during the progression of cervical carcinogenesis was accompanied by an emergence in the upregulation of stroma markers, alpha - smooth muscle actin ( alpha - SMA) and desmin.	"human	41	46	Organism"	"surgical specimens	47	65	Cancer"	"TSP - 1	102	109	Gene_or_gene_product"	"cervical	136	144	Multi"	"stroma markers	215	229	Gene_or_gene_product"	"alpha - smooth muscle actin	231	258	Gene_or_gene_product"	"alpha - SMA	261	272	Gene_or_gene_product"	"desmin	278	284	Gene_or_gene_product"	"[{""token"": ""human"", ""start_span"": 41, ""end_span"": 46, ""type"": ""Organism""}, {""token"": ""surgical specimens"", ""start_span"": 47, ""end_span"": 65, ""type"": ""Cancer""}, {""token"": ""TSP - 1"", ""start_span"": 102, ""end_span"": 109, ""type"": ""Gene_or_gene_product""}, {""token"": ""cervical"", ""start_span"": 136, ""end_span"": 144, ""type"": ""Multi""}, {""token"": ""stroma markers"", ""start_span"": 215, ""end_span"": 229, ""type"": ""Gene_or_gene_product""}, {""token"": ""alpha - smooth muscle actin"", ""start_span"": 231, ""end_span"": 258, ""type"": ""Gene_or_gene_product""}, {""token"": ""alpha - SMA"", ""start_span"": 261, ""end_span"": 272, ""type"": ""Gene_or_gene_product""}, {""token"": ""desmin"", ""start_span"": 278, ""end_span"": 284, ""type"": ""Gene_or_gene_product""}]"
PURPOSE: We prepared tumor endothelium targeted cRGD - modified heparin derivative ( cRGD - HL) by coupling heparin - lithocholic acid ( HL) with cRGDyK, and evaluated inhibition effects of cRGD - HL on angiogenesis and tumor growth.	"tumor endothelium	21	38	Tissue"	"cRGD - modified heparin derivative	48	82	Chemical"	"cRGD - HL	85	94	Chemical"	"heparin - lithocholic acid	108	134	Chemical"	"HL	137	139	Chemical"	"cRGDyK	146	152	Chemical"	"cRGD - HL	190	199	Chemical"	"tumor	220	225	Cancer"	"[{""token"": ""tumor endothelium"", ""start_span"": 21, ""end_span"": 38, ""type"": ""Tissue""}, {""token"": ""cRGD - modified heparin derivative"", ""start_span"": 48, ""end_span"": 82, ""type"": ""Chemical""}, {""token"": ""cRGD - HL"", ""start_span"": 85, ""end_span"": 94, ""type"": ""Chemical""}, {""token"": ""heparin - lithocholic acid"", ""start_span"": 108, ""end_span"": 134, ""type"": ""Chemical""}, {""token"": ""HL"", ""start_span"": 137, ""end_span"": 139, ""type"": ""Chemical""}, {""token"": ""cRGDyK"", ""start_span"": 146, ""end_span"": 152, ""type"": ""Chemical""}, {""token"": ""cRGD - HL"", ""start_span"": 190, ""end_span"": 199, ""type"": ""Chemical""}, {""token"": ""tumor"", ""start_span"": 220, ""end_span"": 225, ""type"": ""Cancer""}]"
The cell autonomous function of p53 in melanocytes is not well described, however, the balance of the evidence suggests that p53 is an effective tumor suppressor and the myriad of mechanisms by which the p53 pathway may be dysregulated in tumors attests to it importance as a tumor suppressor.	"cell	4	8	Cell"	"p53	32	35	Gene_or_gene_product"	"melanocytes	39	50	Cell"	"p53	125	128	Gene_or_gene_product"	"tumor	145	150	Cancer"	"p53	204	207	Gene_or_gene_product"	"tumors	239	245	Cancer"	"tumor	276	281	Cancer"	"[{""token"": ""cell"", ""start_span"": 4, ""end_span"": 8, ""type"": ""Cell""}, {""token"": ""p53"", ""start_span"": 32, ""end_span"": 35, ""type"": ""Gene_or_gene_product""}, {""token"": ""melanocytes"", ""start_span"": 39, ""end_span"": 50, ""type"": ""Cell""}, {""token"": ""p53"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor"", ""start_span"": 145, ""end_span"": 150, ""type"": ""Cancer""}, {""token"": ""p53"", ""start_span"": 204, ""end_span"": 207, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumors"", ""start_span"": 239, ""end_span"": 245, ""type"": ""Cancer""}, {""token"": ""tumor"", ""start_span"": 276, ""end_span"": 281, ""type"": ""Cancer""}]"
Oxygen consumption of HepG2 cells supported by either pyruvate / malate or succinate was inhibited when cells were pre - incubated with 3 - BrPA in glucose - free medium.	"Oxygen	0	6	Chemical"	"HepG2 cells	22	33	Cell"	"pyruvate	54	62	Chemical"	"malate	65	71	Chemical"	"succinate	75	84	Chemical"	"cells	104	109	Cell"	"3 - BrPA	136	144	Chemical"	"glucose	148	155	Chemical"	"[{""token"": ""Oxygen"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Chemical""}, {""token"": ""HepG2 cells"", ""start_span"": 22, ""end_span"": 33, ""type"": ""Cell""}, {""token"": ""pyruvate"", ""start_span"": 54, ""end_span"": 62, ""type"": ""Chemical""}, {""token"": ""malate"", ""start_span"": 65, ""end_span"": 71, ""type"": ""Chemical""}, {""token"": ""succinate"", ""start_span"": 75, ""end_span"": 84, ""type"": ""Chemical""}, {""token"": ""cells"", ""start_span"": 104, ""end_span"": 109, ""type"": ""Cell""}, {""token"": ""3 - BrPA"", ""start_span"": 136, ""end_span"": 144, ""type"": ""Chemical""}, {""token"": ""glucose"", ""start_span"": 148, ""end_span"": 155, ""type"": ""Chemical""}]"
An increase in oligomycin - independent respiration was observed in HepG2 cells treated with 3 - BrPA only when incubated in glucose - supplemented medium, indicating that 3 - BrPA induces mitochondrial proton leakage as well as blocking the electron transport system.	"oligomycin	15	25	Chemical"	"HepG2 cells	68	79	Cell"	"3 - BrPA	93	101	Chemical"	"glucose	125	132	Chemical"	"3 - BrPA	172	180	Chemical"	"mitochondrial	189	202	Cellular_component"	"proton	203	209	Chemical"	"electron	242	250	Chemical"	"[{""token"": ""oligomycin"", ""start_span"": 15, ""end_span"": 25, ""type"": ""Chemical""}, {""token"": ""HepG2 cells"", ""start_span"": 68, ""end_span"": 79, ""type"": ""Cell""}, {""token"": ""3 - BrPA"", ""start_span"": 93, ""end_span"": 101, ""type"": ""Chemical""}, {""token"": ""glucose"", ""start_span"": 125, ""end_span"": 132, ""type"": ""Chemical""}, {""token"": ""3 - BrPA"", ""start_span"": 172, ""end_span"": 180, ""type"": ""Chemical""}, {""token"": ""mitochondrial"", ""start_span"": 189, ""end_span"": 202, ""type"": ""Cellular_component""}, {""token"": ""proton"", ""start_span"": 203, ""end_span"": 209, ""type"": ""Chemical""}, {""token"": ""electron"", ""start_span"": 242, ""end_span"": 250, ""type"": ""Chemical""}]"
All of these results indicate that Akt / mTOR - dependent translation of HIF - 1alpha plays a critical role in the postirradiation up - regulation of intratumoral HIF - 1 activity in response to radiation - induced alterations of glucose and oxygen availability in a solid tumor.	"Akt	35	38	Gene_or_gene_product"	"mTOR	41	45	Gene_or_gene_product"	"HIF - 1alpha	73	85	Gene_or_gene_product"	"intratumoral	150	162	Cancer"	"HIF - 1	163	170	Gene_or_gene_product"	"glucose	230	237	Chemical"	"oxygen	242	248	Chemical"	"solid tumor	267	278	Cancer"	"[{""token"": ""Akt"", ""start_span"": 35, ""end_span"": 38, ""type"": ""Gene_or_gene_product""}, {""token"": ""mTOR"", ""start_span"": 41, ""end_span"": 45, ""type"": ""Gene_or_gene_product""}, {""token"": ""HIF - 1alpha"", ""start_span"": 73, ""end_span"": 85, ""type"": ""Gene_or_gene_product""}, {""token"": ""intratumoral"", ""start_span"": 150, ""end_span"": 162, ""type"": ""Cancer""}, {""token"": ""HIF - 1"", ""start_span"": 163, ""end_span"": 170, ""type"": ""Gene_or_gene_product""}, {""token"": ""glucose"", ""start_span"": 230, ""end_span"": 237, ""type"": ""Chemical""}, {""token"": ""oxygen"", ""start_span"": 242, ""end_span"": 248, ""type"": ""Chemical""}, {""token"": ""solid tumor"", ""start_span"": 267, ""end_span"": 278, ""type"": ""Cancer""}]"
We used microdialysis to sample IL - 8 in normal human breast tissue in situ in pre - and postmenopausal women, preoperatively in breast cancers of women, and in experimental breast cancer in mice.	"IL - 8	32	38	Gene_or_gene_product"	"human	49	54	Organism"	"breast tissue	55	68	Tissue"	"women	105	110	Organism"	"breast cancers	130	144	Cancer"	"women	148	153	Organism"	"breast cancer	175	188	Cancer"	"mice	192	196	Organism"	"[{""token"": ""IL - 8"", ""start_span"": 32, ""end_span"": 38, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Organism""}, {""token"": ""breast tissue"", ""start_span"": 55, ""end_span"": 68, ""type"": ""Tissue""}, {""token"": ""women"", ""start_span"": 105, ""end_span"": 110, ""type"": ""Organism""}, {""token"": ""breast cancers"", ""start_span"": 130, ""end_span"": 144, ""type"": ""Cancer""}, {""token"": ""women"", ""start_span"": 148, ""end_span"": 153, ""type"": ""Organism""}, {""token"": ""breast cancer"", ""start_span"": 175, ""end_span"": 188, ""type"": ""Cancer""}, {""token"": ""mice"", ""start_span"": 192, ""end_span"": 196, ""type"": ""Organism""}]"
In experimental breast cancer, estradiol increased IL - 8 whereas the anti - estrogen tamoxifen inhibited the secretion of IL - 8 both in vitro and extracellularly in vivo in tumors of nude mice.	"breast cancer	16	29	Cancer"	"estradiol	31	40	Chemical"	"IL - 8	51	57	Gene_or_gene_product"	"estrogen	77	85	Chemical"	"tamoxifen	86	95	Chemical"	"IL - 8	123	129	Gene_or_gene_product"	"tumors	175	181	Cancer"	"nude mice	185	194	Organism"	"[{""token"": ""breast cancer"", ""start_span"": 16, ""end_span"": 29, ""type"": ""Cancer""}, {""token"": ""estradiol"", ""start_span"": 31, ""end_span"": 40, ""type"": ""Chemical""}, {""token"": ""IL - 8"", ""start_span"": 51, ""end_span"": 57, ""type"": ""Gene_or_gene_product""}, {""token"": ""estrogen"", ""start_span"": 77, ""end_span"": 85, ""type"": ""Chemical""}, {""token"": ""tamoxifen"", ""start_span"": 86, ""end_span"": 95, ""type"": ""Chemical""}, {""token"": ""IL - 8"", ""start_span"": 123, ""end_span"": 129, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumors"", ""start_span"": 175, ""end_span"": 181, ""type"": ""Cancer""}, {""token"": ""nude mice"", ""start_span"": 185, ""end_span"": 194, ""type"": ""Organism""}]"
Exposure of wild - type primary mouse cerebral endothelial cells to the CD47 ligand thrombospondin 1 ( TSP - 1) induced an increasing amount of cell death, whereas cytotoxicity was significantly decreased in cerebral endothelial cells derived from CD47 knockout mice.	"mouse	32	37	Organism"	"cerebral endothelial cells	38	64	Cell"	"CD47	72	76	Gene_or_gene_product"	"thrombospondin 1	84	100	Gene_or_gene_product"	"TSP - 1	103	110	Gene_or_gene_product"	"cell	144	148	Cell"	"cerebral endothelial cells	208	234	Cell"	"CD47	248	252	Gene_or_gene_product"	"[{""token"": ""mouse"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Organism""}, {""token"": ""cerebral endothelial cells"", ""start_span"": 38, ""end_span"": 64, ""type"": ""Cell""}, {""token"": ""CD47"", ""start_span"": 72, ""end_span"": 76, ""type"": ""Gene_or_gene_product""}, {""token"": ""thrombospondin 1"", ""start_span"": 84, ""end_span"": 100, ""type"": ""Gene_or_gene_product""}, {""token"": ""TSP - 1"", ""start_span"": 103, ""end_span"": 110, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 144, ""end_span"": 148, ""type"": ""Cell""}, {""token"": ""cerebral endothelial cells"", ""start_span"": 208, ""end_span"": 234, ""type"": ""Cell""}, {""token"": ""CD47"", ""start_span"": 248, ""end_span"": 252, ""type"": ""Gene_or_gene_product""}]"
A putative progestin - response element was identified in the human TSP - 1 promoter, which is consistent with the hypothesis that a progestin - PR complex might directly regulate transcription of the TSP - 1 gene in human cells.	"progestin	11	20	Chemical"	"human	62	67	Organism"	"TSP - 1	68	75	Gene_or_gene_product"	"progestin	133	142	Chemical"	"PR	145	147	Gene_or_gene_product"	"TSP - 1	201	208	Gene_or_gene_product"	"human	217	222	Organism"	"cells	223	228	Cell"	"[{""token"": ""progestin"", ""start_span"": 11, ""end_span"": 20, ""type"": ""Chemical""}, {""token"": ""human"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Organism""}, {""token"": ""TSP - 1"", ""start_span"": 68, ""end_span"": 75, ""type"": ""Gene_or_gene_product""}, {""token"": ""progestin"", ""start_span"": 133, ""end_span"": 142, ""type"": ""Chemical""}, {""token"": ""PR"", ""start_span"": 145, ""end_span"": 147, ""type"": ""Gene_or_gene_product""}, {""token"": ""TSP - 1"", ""start_span"": 201, ""end_span"": 208, ""type"": ""Gene_or_gene_product""}, {""token"": ""human"", ""start_span"": 217, ""end_span"": 222, ""type"": ""Organism""}, {""token"": ""cells"", ""start_span"": 223, ""end_span"": 228, ""type"": ""Cell""}]"
Furthermore, overexpression of TLX in Ink4a / Arf ( - / -) astrocytes inhibited cell migration and invasion and promoted neurosphere formation and Nestin expression, which are hallmark characteristics of glioma stem cells, under stem cell culture conditions.	"TLX	31	34	Gene_or_gene_product"	"Ink4a	38	43	Gene_or_gene_product"	"Arf	46	49	Gene_or_gene_product"	"cell	80	84	Cell"	"neurosphere	121	132	Cell"	"Nestin	147	153	Gene_or_gene_product"	"glioma stem cells	204	221	Cell"	"stem cell	229	238	Cell"	"[{""token"": ""TLX"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Gene_or_gene_product""}, {""token"": ""Ink4a"", ""start_span"": 38, ""end_span"": 43, ""type"": ""Gene_or_gene_product""}, {""token"": ""Arf"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Gene_or_gene_product""}, {""token"": ""cell"", ""start_span"": 80, ""end_span"": 84, ""type"": ""Cell""}, {""token"": ""neurosphere"", ""start_span"": 121, ""end_span"": 132, ""type"": ""Cell""}, {""token"": ""Nestin"", ""start_span"": 147, ""end_span"": 153, ""type"": ""Gene_or_gene_product""}, {""token"": ""glioma stem cells"", ""start_span"": 204, ""end_span"": 221, ""type"": ""Cell""}, {""token"": ""stem cell"", ""start_span"": 229, ""end_span"": 238, ""type"": ""Cell""}]"
Adult mutants became sterile males due to the meiotic arrest of spermatocytes, which then died by apoptosis, followed by neoplastic proliferation of gonad somatic cells that was similar to neoplasia observed in ageing dead end ( dnd) - knockdown males, which lack germ cells.	"Adult mutants	0	13	Organism"	"spermatocytes	64	77	Cell"	"neoplastic	121	131	Cancer"	"gonad somatic cells	149	168	Cell"	"neoplasia	189	198	Pathological_formation"	"dead end	218	226	Gene_or_gene_product"	"dnd	229	232	Gene_or_gene_product"	"germ cells	264	274	Cell"	"[{""token"": ""Adult mutants"", ""start_span"": 0, ""end_span"": 13, ""type"": ""Organism""}, {""token"": ""spermatocytes"", ""start_span"": 64, ""end_span"": 77, ""type"": ""Cell""}, {""token"": ""neoplastic"", ""start_span"": 121, ""end_span"": 131, ""type"": ""Cancer""}, {""token"": ""gonad somatic cells"", ""start_span"": 149, ""end_span"": 168, ""type"": ""Cell""}, {""token"": ""neoplasia"", ""start_span"": 189, ""end_span"": 198, ""type"": ""Pathological_formation""}, {""token"": ""dead end"", ""start_span"": 218, ""end_span"": 226, ""type"": ""Gene_or_gene_product""}, {""token"": ""dnd"", ""start_span"": 229, ""end_span"": 232, ""type"": ""Gene_or_gene_product""}, {""token"": ""germ cells"", ""start_span"": 264, ""end_span"": 274, ""type"": ""Cell""}]"
The expression of ARD1 was augmented by treatment with synthetic androgen ( R1881) unless AR is deficient or is inhibited by AR - specific siRNA or androgen inhibitor bicalutamide ( Casodex).	"ARD1	18	22	Gene_or_gene_product"	"androgen	65	73	Chemical"	"R1881	76	81	Chemical"	"AR	90	92	Gene_or_gene_product"	"AR	125	127	Gene_or_gene_product"	"androgen	148	156	Chemical"	"bicalutamide	167	179	Chemical"	"Casodex	182	189	Chemical"	"[{""token"": ""ARD1"", ""start_span"": 18, ""end_span"": 22, ""type"": ""Gene_or_gene_product""}, {""token"": ""androgen"", ""start_span"": 65, ""end_span"": 73, ""type"": ""Chemical""}, {""token"": ""R1881"", ""start_span"": 76, ""end_span"": 81, ""type"": ""Chemical""}, {""token"": ""AR"", ""start_span"": 90, ""end_span"": 92, ""type"": ""Gene_or_gene_product""}, {""token"": ""AR"", ""start_span"": 125, ""end_span"": 127, ""type"": ""Gene_or_gene_product""}, {""token"": ""androgen"", ""start_span"": 148, ""end_span"": 156, ""type"": ""Chemical""}, {""token"": ""bicalutamide"", ""start_span"": 167, ""end_span"": 179, ""type"": ""Chemical""}, {""token"": ""Casodex"", ""start_span"": 182, ""end_span"": 189, ""type"": ""Chemical""}]"
The activity of type IV collagenase, which enables tumor cells to degrade collagen type IV found in the subendothelial basement membrane, has been correlated with the metastatic potential in several tumor types, including the rat 13762NF mammary adenocarcinoma cell line and its clones.	"type IV collagenase	16	35	Gene_or_gene_product"	"tumor cells	51	62	Cell"	"collagen type IV	74	90	Gene_or_gene_product"	"subendothelial basement membrane	104	136	Cellular_component"	"tumor	199	204	Cancer"	"rat	226	229	Organism"	"13762NF mammary adenocarcinoma cell line	230	270	Cell"	"clones	279	285	Cell"	"[{""token"": ""type IV collagenase"", ""start_span"": 16, ""end_span"": 35, ""type"": ""Gene_or_gene_product""}, {""token"": ""tumor cells"", ""start_span"": 51, ""end_span"": 62, ""type"": ""Cell""}, {""token"": ""collagen type IV"", ""start_span"": 74, ""end_span"": 90, ""type"": ""Gene_or_gene_product""}, {""token"": ""subendothelial basement membrane"", ""start_span"": 104, ""end_span"": 136, ""type"": ""Cellular_component""}, {""token"": ""tumor"", ""start_span"": 199, ""end_span"": 204, ""type"": ""Cancer""}, {""token"": ""rat"", ""start_span"": 226, ""end_span"": 229, ""type"": ""Organism""}, {""token"": ""13762NF mammary adenocarcinoma cell line"", ""start_span"": 230, ""end_span"": 270, ""type"": ""Cell""}, {""token"": ""clones"", ""start_span"": 279, ""end_span"": 285, ""type"": ""Cell""}]"
Cells of the highly metastatic lung - colonizing clone MTF7. T35. 3, derived from the 13762NF cell line, were treated for 3 days with 0. 1, 1, or 10 microM all - trans - RA, harvested, and seeded on [ 3H] proline - labeled extracellular matrix deposited by cultured rat lung endothelial cells or on a film of purified [ 3H] proline - labeled type IV collagen.	"Cells	0	5	Cell"	"lung	31	35	Organ"	"13762NF cell line	86	103	Cell"	"all - trans - RA	156	172	Chemical"	"extracellular matrix	223	243	Cellular_component"	"rat	266	269	Organism"	"lung endothelial cells	270	292	Cell"	"type IV collagen	342	358	Gene_or_gene_product"	"[{""token"": ""Cells"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Cell""}, {""token"": ""lung"", ""start_span"": 31, ""end_span"": 35, ""type"": ""Organ""}, {""token"": ""13762NF cell line"", ""start_span"": 86, ""end_span"": 103, ""type"": ""Cell""}, {""token"": ""all - trans - RA"", ""start_span"": 156, ""end_span"": 172, ""type"": ""Chemical""}, {""token"": ""extracellular matrix"", ""start_span"": 223, ""end_span"": 243, ""type"": ""Cellular_component""}, {""token"": ""rat"", ""start_span"": 266, ""end_span"": 269, ""type"": ""Organism""}, {""token"": ""lung endothelial cells"", ""start_span"": 270, ""end_span"": 292, ""type"": ""Cell""}, {""token"": ""type IV collagen"", ""start_span"": 342, ""end_span"": 358, ""type"": ""Gene_or_gene_product""}]"
In examining the metabolic basis for selenoperoxidase - dependent resistance, we found that glucose - replete Se ( -) cells reduce t - BuOOH to t - butanol far more slowly than Se ( +) cells, the ratio of the first - order rate constants approximating that of the GPX activities ( L1210 cells) or PHGPX activities ( K562 cells).	"selenoperoxidase	37	53	Gene_or_gene_product"	"glucose	92	99	Chemical"	"t - BuOOH	131	140	Chemical"	"t - butanol	144	155	Chemical"	"GPX	264	267	Gene_or_gene_product"	"L1210 cells	281	292	Cell"	"PHGPX	297	302	Gene_or_gene_product"	"K562 cells	316	326	Cell"	"[{""token"": ""selenoperoxidase"", ""start_span"": 37, ""end_span"": 53, ""type"": ""Gene_or_gene_product""}, {""token"": ""glucose"", ""start_span"": 92, ""end_span"": 99, ""type"": ""Chemical""}, {""token"": ""t - BuOOH"", ""start_span"": 131, ""end_span"": 140, ""type"": ""Chemical""}, {""token"": ""t - butanol"", ""start_span"": 144, ""end_span"": 155, ""type"": ""Chemical""}, {""token"": ""GPX"", ""start_span"": 264, ""end_span"": 267, ""type"": ""Gene_or_gene_product""}, {""token"": ""L1210 cells"", ""start_span"": 281, ""end_span"": 292, ""type"": ""Cell""}, {""token"": ""PHGPX"", ""start_span"": 297, ""end_span"": 302, ""type"": ""Gene_or_gene_product""}, {""token"": ""K562 cells"", ""start_span"": 316, ""end_span"": 326, ""type"": ""Cell""}]"
Interestingly, crossing of cyclin D1 transgenic mice with E mu L - myc transgenics that express their transgene in both B - and T - cells but predominantly develop T - cell tumours leads in double transgenics exclusively to B - cell neoplasia.	"cyclin D1	27	36	Gene_or_gene_product"	"E mu	58	62	Gene_or_gene_product"	"L - myc	63	70	Gene_or_gene_product"	"B -	120	123	Cell"	"T - cells	128	137	Cell"	"T - cell tumours	164	180	Cancer"	"transgenics	197	208	Organism"	"B - cell neoplasia	224	242	Cell"	"[{""token"": ""cyclin D1"", ""start_span"": 27, ""end_span"": 36, ""type"": ""Gene_or_gene_product""}, {""token"": ""E mu"", ""start_span"": 58, ""end_span"": 62, ""type"": ""Gene_or_gene_product""}, {""token"": ""L - myc"", ""start_span"": 63, ""end_span"": 70, ""type"": ""Gene_or_gene_product""}, {""token"": ""B -"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Cell""}, {""token"": ""T - cells"", ""start_span"": 128, ""end_span"": 137, ""type"": ""Cell""}, {""token"": ""T - cell tumours"", ""start_span"": 164, ""end_span"": 180, ""type"": ""Cancer""}, {""token"": ""transgenics"", ""start_span"": 197, ""end_span"": 208, ""type"": ""Organism""}, {""token"": ""B - cell neoplasia"", ""start_span"": 224, ""end_span"": 242, ""type"": ""Cell""}]"
Little difference was observed in their transforming efficiency ( 0. 2 - 0. 3 transformants / micrograms DNA) between the combinations of oncogenes applied but a tendency was noted that cells transfected with ras or src in combination with myc developed the capacity to grow for a longer period and differentiated at a later stage than those transfected solely with ras or src.	"transformants	78	91	Cell"	"DNA	105	108	Cellular_component"	"cells	186	191	Cell"	"ras	209	212	Gene_or_gene_product"	"src	216	219	Gene_or_gene_product"	"myc	240	243	Gene_or_gene_product"	"ras	366	369	Gene_or_gene_product"	"src	373	376	Gene_or_gene_product"	"[{""token"": ""transformants"", ""start_span"": 78, ""end_span"": 91, ""type"": ""Cell""}, {""token"": ""DNA"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Cellular_component""}, {""token"": ""cells"", ""start_span"": 186, ""end_span"": 191, ""type"": ""Cell""}, {""token"": ""ras"", ""start_span"": 209, ""end_span"": 212, ""type"": ""Gene_or_gene_product""}, {""token"": ""src"", ""start_span"": 216, ""end_span"": 219, ""type"": ""Gene_or_gene_product""}, {""token"": ""myc"", ""start_span"": 240, ""end_span"": 243, ""type"": ""Gene_or_gene_product""}, {""token"": ""ras"", ""start_span"": 366, ""end_span"": 369, ""type"": ""Gene_or_gene_product""}, {""token"": ""src"", ""start_span"": 373, ""end_span"": 376, ""type"": ""Gene_or_gene_product""}]"
By introducing a cDNA library derived from rat embryonic fibroblast cells, we isolated several morphologically flat revertants of rat 3Y1 cells transformed by the E6 and E7 genes of human papillomavirus type 18 ( HPV18).	"rat	43	46	Organism"	"embryonic fibroblast cells	47	73	Cell"	"rat	130	133	Organism"	"3Y1 cells	134	143	Cell"	"E6	163	165	Gene_or_gene_product"	"E7	170	172	Gene_or_gene_product"	"human papillomavirus type 18	182	210	Organism"	"HPV18	213	218	Organism"	"[{""token"": ""rat"", ""start_span"": 43, ""end_span"": 46, ""type"": ""Organism""}, {""token"": ""embryonic fibroblast cells"", ""start_span"": 47, ""end_span"": 73, ""type"": ""Cell""}, {""token"": ""rat"", ""start_span"": 130, ""end_span"": 133, ""type"": ""Organism""}, {""token"": ""3Y1 cells"", ""start_span"": 134, ""end_span"": 143, ""type"": ""Cell""}, {""token"": ""E6"", ""start_span"": 163, ""end_span"": 165, ""type"": ""Gene_or_gene_product""}, {""token"": ""E7"", ""start_span"": 170, ""end_span"": 172, ""type"": ""Gene_or_gene_product""}, {""token"": ""human papillomavirus type 18"", ""start_span"": 182, ""end_span"": 210, ""type"": ""Organism""}, {""token"": ""HPV18"", ""start_span"": 213, ""end_span"": 218, ""type"": ""Organism""}]"
